

HVAX



HORIZONS ETFs
by Mirae Asset

Horizons Global Vaccines and Infectious Diseases Index ETF

ETF Snapshot

Get Exposure to the Companies Leading Vaccine Development

The ongoing COVID-19 pandemic has demonstrated that vaccines are an essential tool in protecting global populations and have led to the near-eradication of life-threatening illnesses such as Smallpox and Polio. By safeguarding the public, vaccines help ensure that people can continue to work and supply chains continue to move, highlighting their value preserving and protecting the global economy.

The life sciences and pharmaceutical companies that develop these treatments are also benefitting. Due to the renewed importance of vaccines, cutting-edge therapies and pandemic preparedness the healthcare sector has received massive capital infusions, which could potentially propel further transformative innovation.

The Horizons Global Vaccines and Infectious Diseases Index ETF (HVAX), allows investors to gain exposure to the potentially long-term theme of vaccine development and disease prevention.

HVAX seeks to replicate, to the extent possible and net of expenses, the performance of an index that is designed to provide exposure to the performance of global, publicly listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics. Currently, HVAX seeks to replicate, directly or indirectly, the performance of the Solactive Global Vaccines and Infectious Diseases Index, net of expenses. HVAX seeks to hedge any U.S. dollar portfolio exposure back to the Canadian dollar at all times.

Name:

The Horizons Global Vaccines and Infectious Diseases Index ETF

Launch Date:

October 27, 2021

Ticker:

HVAX

Management Fee:

0.60% (Plus applicable sales taxes.)

Investment Manager:

Horizons ETFs Management (Canada) Inc.

Underlying Index:

Solactive Global Vaccines and Infectious Diseases Index

Bloomberg Index Ticker:

SOCGVAXN

Currency Hedged:

USD exposure

Distributions Frequency:

Annually, if any

Eligibility:

All registered and non-registered investment accounts

Horizons Global Vaccines and Infectious Diseases Index ETF

Key Features

A Renewed Focus on Disease Prevention

There are four key areas of healthcare research and development that will aid in preventing future global pandemics or potentially eradicating existing infectious diseases.



Vaccines: Vaccine development is a key focus of healthcare research and development (R&D) and the primary science-based technology available to combat infectious diseases. By 2024, the global vaccines market is projected to reach \$58.4 billion at a CAGR of 7.0%*. The growth is attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development and the rising focus on immunization.



Diagnostics: Diagnostics in the prevention and identification of diseases is arguably just as crucial a line of defense against infectious disease as vaccines.



Therapeutics: This is part of the industry focused on key pharmaceutical treatments such as antiviral drugs or important biotechnology treatments such as antibodies. This has been a key area of growth as researchers look to find drug or clinical treatments that can be used to help prevent mortality and symptoms of disease.




Genomics: Genomics focuses on DNA and genetic research to create more effective therapeutic treatments. This area of study was a key determinant in the development of Pfizer/BioNTech and Moderna mRNA vaccine technology.

*Source: <https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html>

Key Features

- Provides globally diversified exposure to leading companies that provide research, medicines and vaccines against infectious diseases
- Massive public and private investment during COVID-19 pandemic driving exciting innovation in vaccine and pharmaceutical development
- COVID-19 has likely created a long-term focus on global disease prevention, a potentially long-term trend
- Substantial revenue opportunities from further vaccine and infectious disease development beyond COVID-19



Horizons Global Vaccines and Infectious Diseases Index ETF

Underlying Index

Solactive Global Vaccines and Infectious Diseases Index

The Solactive Global Vaccines and Infectious Diseases Index (the “Underlying Index”), is designed to provide exposure to the performance of global, publicly-listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics.

Constituents issuers will be drawn from publicly listed companies in developed and emerging markets, and may include small, mid and large-capitalization companies. The Underlying Index will not include securities that trade on the Shanghai and Shenzhen Connect exchanges but may include securities which have Hong-Kong listed shares or ADRs. In addition, a company must meet minimum trading, liquidity and market capitalization requirements to be considered for inclusion.

The Underlying Index uses an innovative natural language processing algorithm, known as ARTIS, a proprietary tool of Solactive, which is built to identify thematic exposure in corporations using unconventional data sources. ARTIS uses keywords to identify companies that have or are expected to have significant exposure in the theme of involvement in the development and production of vaccines, therapeutics and diagnostics.

To learn more, please visit www.HorizonsETFs.com/ETF/HVAX



Commissions, management fees and expenses all may be associated with an investment in The Horizons Global Vaccines and Infectious Diseases Index ETF (the “ETF”) managed by Horizons ETFs Management (Canada) Inc. The ETF is not guaranteed, its values change frequently and past performance may not be repeated. The prospectus contains important detailed information about the ETF. **Please read the prospectus before investing.**

The financial instrument is not sponsored, promoted, sold or supported in any other manner by Solactive AG nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade name or the Index Price at any time or in any other respect. The Index is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Issuer, Solactive AG has no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the financial instrument. Neither publication of the Index by Solactive AG nor the licensing of the Index or Index trade name for the purpose of use in connection with the financial instrument constitutes a recommendation by Solactive AG to invest capital in said financial instrument nor does it in any way represent an assurance or opinion of Solactive AG with regard to any investment in this financial instrument.